GlaxoSmithKline (NYSE: GSK) reported Q4 EPS of GBP0.23, GBP0.26 worse than the analyst estimate of GBP0.49. Revenue for the quarter came in at GBP8.12 billion versus the consensus estimate of GBP9.86 billion.

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.